Background: This is a randomized, double-blind, dose-ranging study in patients receiving highly emetogenic chemotherapy (HEC) to evaluate the safety, efficacy, and pharmacokinetics of palonosetron, in combination with dexamethasone. Results: In this study, all patients were given ‡50 mg/m 2 cisplatin, which was considered to be HEC. No significant differences in complete response (CR: no emesis and no rescue medication) rates were found in the first 24 h between the 0.075-, 0.25-, and 0.75-mg groups (77.6%, 81.8%, and 79.5%, respectively). In the 120-h period of overall observation, CR rates increased in a dose-dependent manner. In the 0.75-mg group, we observed a significantly longer time to treatment failure than in the 0.075-mg group (median time >120 versus 82.0 h, P = 0.038). Palonosetron was tolerated well and did not show any dose-related increase in adverse effects.
Palonosetron has higher affinity for the serotonin receptor and a longer half-life in plasma than previous 5-HT 3 receptor antagonists [6, 7] . In a phase II, dose-ranging randomized study, Eisenberg et al. [8] reported that 3 and 10 lg/kg i.v. palonosetron (equivalent to fixed doses of 0.25 and 0.75 mg) were the lowest effective doses to prevent CINV in patients treated with HEC. In this phase II study, palonosetron was used without corticosteroid therapy: at that time the use of dexamethasone as a concomitant antiemetic was not part of clinical practice.
In a phase III trial carried out in Europe and in the United States, palonosetron was given at single doses of 0.25 and 0.75 mg and compared with a single 32-mg dose of ondansetron to prevent nausea and vomiting induced by HEC [9] . Dexamethasone, the use of which has now been introduced in clinical practice [10] [11] [12] [13] , was allowed, at the discretion of the investigators only as a single administration before chemotherapy: under these conditions dexamethasone was administered to 67% of patients. Patients pretreated with 0.25-mg palonosetron plus dexamethasone had significantly higher complete response (CR) rates than those receiving ondansetron plus dexamethasone during both the delayed (42.0% versus 28.6%) and overall (40.7% versus 25.2%) phases. In all patients, palonosetron showed CR rates similar to ondansetron at three observation periods: acute, delayed, and overall phases (0-24, 24-120, and 0-120 h, respectively). No clinically relevant differences were noted between the two doses (0.25 and 0.75 mg) in either efficacy or safety.
No 5-HT 3 receptor antagonists have yet been approved in Japan for both acute and delayed CINV. A phase I trial of palonosetron in healthy Japanese volunteers showed similar pharmacokinetic profiles in Japanese and US populations [6] . The present randomized, double-blind phase II trial sought to determine the fully effective and safe dose range of palonosetron in patients in Japan receiving HEC with three fixed doses (0.075, 0.25, and 0.75 mg) combined with dexamethasone. Safety was assessed for 14 days after palonosetron administration. The pharmacokinetic profile of palonosetron was assessed in a subgroup of patients.
materials and methods
The study was conducted according to the Declaration of Helsinki, and written approval was obtained from the institutional review boards at each site before study commencement. All patients provided written informed consent before enrollment. A total of 34 Japanese hospitals were involved from April to October 2005.
patient population
The study enrolled patients 20-79 years old with confirmed diagnoses of cancer. Subjects were either naive to chemotherapy or had received only low or minimally emetogenic chemotherapies. They had an Eastern Cooperative Oncology Group performance status of zero or one and were scheduled to receive one cycle of HEC (including ‡50 mg/m 2 cisplatin, >1500 mg/m 2 cyclophosphamide or dacarbazine). Adequate hepatorenal function (white blood cell ‡3000/mm 3 , aspartate aminotransferase <100 IU/l, alanine aminotransferase <100 IU/l, and creatinine clearance ‡60 ml/ min) was required. 48-50 h after chemotherapy. The doses of dexamethasone used in this study were determined based on the doses employed by previous Japanese clinical studies [16, 17] and on the doses used in clinical practice in Japan.
assessment
All patients were hospitalized at least until the next day following the administration of palonosetron. Efficacy was assessed starting from administration of HEC up to 5 days. Patients recorded the date and time of episodes of emesis and the degree of nausea in diaries. An emetic episode was defined as one episode of vomiting or a sequence of episodes in very close succession not relieved by a period of relaxation of at least 1 min; any number of unproductive emetic episodes (retching) in any given 5-min period; or an episode of retching lasting <5 min combined with vomiting not relieved by a period of relaxation of at least 1 min [18] . Nausea was classified into four grades (0, none; 1, mild; 2, moderate; and 3, severe). Any use of rescue medication was recorded, including drug name, dose, and time of administration. Rescue medication could be administered for an emetic event or nausea or by patient request. Descriptions in diaries were confirmed daily by physicians or nurses, or both.
efficacy parameters
The primary end point was the proportion of patients with a CR (no emesis and no rescue medication) during the acute phase (0-24 h) after chemotherapy. The secondary end points were (i) proportion of patients with CR during the delayed phase (24-120 h) and overall phase (0-120 h) and daily CR rates after administration of chemotherapy; (ii) proportion of patients with complete control (CC: no emetic episode, no rescue medication, and no more than mild nausea) during the acute, delayed, and overall phases; and (iii) time to treatment failure (TTF: time to first emetic episode or first administration of rescue medication).
safety parameters
Vital signs, physical exam, 12-lead electrocardiogram, blood tests, and urinalysis were assessed on days 2, 8, and 15. Safety was also assessed by recording adverse events (AEs) up to 14 days. AEs were assessed using CTCAE by the investigators for intensity and possible association with palonosetron.
pharmacokinetic analysis
Accurate pharmacokinetic evaluation of palonosetron and its N-oxide metabolite (metabolite M9) required at least six patients in each dose group. Over 6 ml of whole blood was collected from patients in the pharmacokinetic study into heparinized vacuum tubes before study drug administration and then at 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 120, and 168 h from then. Plasma was separated from whole blood by centrifugation and stored at 220°C or less until analysis. Palonosetron and metabolite M9 in plasma were determined by liquid chromatography-tandem mass spectrometry after solid-phase extraction. The lower limits of quantification (LLOQ) were 0.05 ng/ml for palonosetron and 0.01 ng/ml for metabolite M9. For pharmacokinetic analysis, the maximum plasma concentration (C max ), area under the plasma concentration-time curve (AUC), terminal half-life (t 1/2 ), total clearance (CL tot ), and volume of distribution in the terminal phase (Vd b ) of individual subjects were calculated to obtain means and standard deviations according to dose groups. All pharmacokinetic parameters were calculated as actual times after administration.
statistical analyses
A number of 72 patients were needed in each group, i.e. 216 patients in total, to obtain 80% statistical power to confirm the dose-response relationship of palonosetron assuming CR rates of 45%, 65%, and 65%, for the 0.075-, 0.25-, and 0.75-mg dose groups, respectively, in the acute phase.
A relationship between dose and response in the acute phase was found using the Cochran-Armitage trend test, with an upper significance level of 2.5%. Based on previous reports, dose-response contrast coefficients of 22, 1, and 1 were assumed for the dose groups [8] . The full analysis set (FAS), defined as patients who received palonosetron and HEC on day 1, was used to assess efficacy. For secondary efficacy end points, CR and CC rates, up to 120 h after HEC, were evaluated every 24 h by groups using 95% confidence intervals (CIs). Generalized estimating equations (GEEs) were applied to the logistic models to evaluate dose response in consideration of all CR assessments carried out every 24 h after administration of HEC. Contrast coefficients were assigned to dose groups in the model to test dose response. TTF was evaluated using the KaplanMeier method with estimation of quartiles and 95% CIs among different dose groups. The number of emetic episodes and frequency of nausea events were summarized every 24 h until 120 h after HEC. Safety was evaluated in the safety analysis group: all patients received palonosetron and underwent at least one safety evaluation. Analyses were made with SAS version 8.0 (SAS Institute, Cary, NC).
In statistical analysis of pharmacokinetic parameters, the dose proportionality for AUC and C max was evaluated using linear and log-log (power) regression models. One-way analysis of variance was used to examine the effect of dose on pharmacokinetic parameters. All parameters were converted to natural logarithms, and AUC and C max were adjusted with dose normalization. results patients A total of 233 patients were enrolled. Two patients were not administered palonosetron because of infection. Palonosetron was therefore given to 231 patients, two of whom withdrew consent for study participation or transferred to another hospital. Subsequent analyses were based on 231 patients given the projected study medication, as the FAS. Baseline characteristics of patients were similar across treatment groups. Approximately 95% of patients had lung cancer (Table 1 ). All patients were administered cisplatin at highly emetogenic doses: only one patient (treated with 0.075 mg) received cisplatin and paclitaxel.
primary efficacy end point
The CR rates during the first 24 h (acute phase) were 77.6%, 81.8%, and 79.5% in the 0.075-, 0.25-, and 0.75-mg dose groups, respectively (Table 2 and Figure 1) . Differences of the CR rates among three dose groups were not significant (upper side P = 0.2858).
secondary efficacy end point CR rates during the delayed and overall phases were higher both in the 0.25-and 0.75-mg groups than in the 0.075-mg group. The CR rates were 40.8%, 53.2%, and 56.4% in the 0.075-, 0.25-, and 0.75-mg groups, respectively, in the delayed phase, and 38.2%, 49.4%, and 56.4%, respectively, in the overall phase ( Table 2 ). The elevation in CR rates with increases in palonosetron doses indicated statistically significant differences among the doses with the given coefficients of 22, 1, and 1 (upper side P = 0.0142 and 0.0108 in delayed and overall phases, respectively). Both the 0.25-and 0.75-mg CR rates were >10% higher than in the 0.075-mg group. original article
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Dose-response relationship in consideration of all CR assessments carried out every 24 h after HEC was evaluated using the GEE logistic model with contrast coefficients assigned to dose groups. Dose response was significant with contrast coefficients of 22, 1, and 1, indicating a statistically significant difference between the 0.075-mg group and the two higher dose groups (Table 3) . CC rates in each group were similar with CR rates (data not shown).
TTF was significantly longer in the 0.75-mg group than in the 0.075-mg group (P = 0.0376, Figure 2 ). The 0.075-mg group had significantly shorter TTF than the combined 0.25-and 0.75-mg groups (P = 0.0491). Median TTFs were 82.0, 117, and >120 h in the 0.075-, 0.25-, and 0.75-mg groups, respectively. safety Safety was assessed in all 231 patients who received palonosetron. All patients experienced at least one AE during the 14-day period after palonosetron, but the majority of these ($60%) were judged to be unrelated or unlikely related to palonosetron, being instead associated with cancer or chemotherapy. Of those patients who suffered from AEs thought to be related to palonosetron, the maximum intensity of the events was mild or moderate in almost all (>90%). AEs related to palonosetron are shown in Table 4 , the most frequent AEs being constipation and headache. The incidence, intensity, and relation of AEs to palonosetron were similar among the 
pharmacokinetics
The pharmacokinetics of palonosetron was examined in 24 eligible patients (Table 5 ). The mean time-to-concentration profiles of palonosetron in plasma for the three dosage groups are illustrated in Figure 3A . The concentration of palonosetron declined relatively rapidly to 6 h and then gradually at an elimination half-life of $40 h thereafter. The concentrations of metabolite M9 were much lower than that of palonosetron ( Figure 3B) . Pharmacokinetic parameters are shown in Table 6 . Inspection of individual concentration-time profiles estimated the terminal elimination phase for palonosetron as 24 h after administration or later. The t 1/2 , CL tot , and Vd b could be calculated for only one patient in the 0.075-mg group because most data in the terminal phase were under the LLOQ. The data indicated a prolonged effective concentration and extensive systemic distribution. Linear and log-log (power) models revealed that AUC and C max were proportional to doses from 0.075 to 0.75 mg. One-way analysis of variance found no significance for any parameter among the three dose levels, suggesting that the pharmacokinetics of palonosetron was proportional to dose.
discussion
We set out to determine whether palonosetron, given on the first day of HEC, in combination with dexamethasone provided dose-dependent antiemetic effects. During the acute phase (day 1), no significant difference was observed in the CR rates among the three dose groups of palonosetron. In contrast to the acute phase, a significant difference in CR rate was observed between the 0.075-mg group and other two dose groups (0.25 and 0.75 mg) by applying a logistic model with the GEE method for the period from 0 to 120 h. The TTF at the highest dose was significantly longer than at the lowest dose.
While in previous studies in Western populations, dexamethasone was not used [8] , patients in the present study received dexamethasone from days 1 to 3. This is due to the evolution of recommendations updated in the currently available guidelines [19] [20] [21] [22] : dexamethasone is now recognized to have an additive antiemetic effect on CINV [10] [11] [12] [13] . The results reflect the current clinical practice whereby 5-HT 3 receptor antagonists and dexamethasone are given in combination. original article
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Palonosetron concentrations in plasma increased with dose, and the dose proportionality of its pharmacokinetics was verified in the patient population of this study. Palonosetron has a much longer t 1/2 than other 5-HT 3 receptor antagonists, as measured both in Western and Japanese patients [6] . Vd b , which generally reflects tissue distribution, was higher than that of other 5-HT 3 receptor antagonists [6] . Thus, a prolonged pharmacological effect can be expected in patients in Japan, as already observed in Western population.
AEs were found in all patients, although the majority was unrelated or unlikely to be related to palonosetron. The main AEs related to palonosetron were constipation and headache, at frequencies of <15% and they were not dose dependent. No serious AE was related to palonosetron, and no patients died during the observation period of this study. The types of AEs were similar to those reported in previous trials [8, 9, 18, 23] .
Our results demonstrated that single 0.25-and 0.75-mg doses of palonosetron given on the first day of HEC, combined with dexamethasone (on three consecutive days beginning on day 1 of treatment), exhibited antiemetic effects in a dose-dependent manner, especially in the overall and delayed observation periods. Both the 0.25-and 0.75-mg doses of palonosetron were identified as effective and tolerated well by patients in Japan. The 0.075 mg dose appeared to be insufficient to completely prevent CINV. Comparison of the effects of palonosetron with those of other 5-HT 3 receptor antagonists in combination with dexamethasone is under investigation. Further studies are required to clarify the best method to administer palonosetron to prevent nausea and vomiting associated with emetogenic chemotherapy. 
